hat
Done prezante isit la demontre ke J-147 poud gen kapasite pou sove defisi kognitif lè yo administre nan yon etap an reta nan maladi a. Kapasite nan J-147 poud amelyore memwa nan sourit AD ki gen rapò ak endiksyon li yo nan faktè yo nerifwofik NGF (faktè kwasans nève) ak BDNF (nan sèvo ki sòti faktè nerotwofik) osi byen ke plizyè BDNF-repons pwoteyin ki enpòtan pou aprann ak memwa. Konparezon ant J-147 (1146963-51-0) poud ak donepezil nan modèl la scopolamine te montre ke pandan tou de konpoze yo te konparab nan sovtaj kout tèm memwa, J-147 poud te siperyè nan sovtaj memwa espasyal ak yon konbinezon de de a te travay pi bon pou memwa kontèks ak cued.
eng
Data presented here demonstrate that J-147 powder has the ability to rescue cognitive deficits when administered at a late stage in the disease. The ability of J-147 powder to improve memory in aged AD mice is correlated with its induction of the neurotrophic factors NGF (nerve growth factor) and BDNF (brain derived neurotrophic factor) as well as several BDNF-responsive proteins which are important for learning and memory. The comparison between J-147(1146963-51-0) powder and donepezil in the scopolamine model showed that while both compounds were comparable at rescuing short term memory, J-147 powder was superior at rescuing spatial memory and a combination of the two worked best for contextual and cued memory.